


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (Cancelled).

9. (New): A compound of formula (I):



wherein:

R^1 represents $-C_{1-6}$ alkyl substituted by 1, 2, or 3 halogen or cyano groups; $-C_{0-4}$ alkyl- C_{3-8} cycloalkyl; $-C_{2-4}$ alkyl-oxy- C_{1-4} alkyl; $-C_{1-4}$ alkyl-aryl, wherein said cycloalkyl or aryl groups of R^1 may be optionally substituted by 1, 2, or 3 groups selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino and trifluoromethyl;

R^2 represents hydrogen or C_{1-6} alkyl;

m represents 1;

R^3 represents hydrogen, methyl or halogen;

R^4 and R^5 independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

A represents phenyl optionally substituted by a halogen, cyano, trifluoromethyl, or trifluoromethoxy group;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (New): The compound according to claim 9, wherein: A is unsubstituted phenyl.

11. (New): A compound which is:

8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

12. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.

13. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 11 and a pharmaceutically acceptable carrier or excipient.

14. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

15. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 11 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

16. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
17. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.
18. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
19. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.
20. (New): A method of Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
21. (New): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.